The molecule is an azo derivative of an active molecule (UR-12715, PAF antagonist and anti-TNFa) and 5-aminosalicylic acid (5-ASA), the gold standard treatment for mild to moderate ulcerative colitis

Azo-reduction of this prodrug by colonic bacteria leads to the release of its active components, both of them being active for the topical treatment of inflammation in the colon.

The molecule is an azo derivative of an active molecule (UR-12715, PAF antagonist and anti-TNFa) and 5-aminosalicylic acid (5-ASA), the gold standard treatment for mild to moderate ulcerative colitis. Azo-reduction of this pro-drug by colonic bacteria leads to the release of its active components, both of them being active for the topical treatment of inflammation in the colon.

The intrinsic activity of the active molecule UR-12715 and its synergy with 5-ASA have been shown in an animal model of colitis. The compound is currently in Phase I.

Phase I

Our outstanding Patent Department ensures that our global IP is protected.

The PoC studies are currently being conducted, as soon as they are complete Palau Pharma will be seeking the best possible partners to collaborate with.